Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Amini

Orthopaedic Surgery Willow Grove, PA Medical Doctor

NPI 1528292166 CMS profile 1175405

2400 Maryland Rd Ste 20, Willow Grove, PA 19090

Open in the dashboard

General payments

$965,574

847 records reported · program years 2019–2025

Research payments

$4,521

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$1,104

1 holding reported · through program year 2025

Research they led as principal investigator

$495,182 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Michael Amini of Willow Grove, PA is reported in the CMS Open Payments database as having received $965,574 across 847 general payments and $4,521 in research payments paid to them. Separately, studies naming them as principal investigator received $495,182 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,104 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $272,139 183
2024 General $230,079 176
2023 General $145,574 139
2022 General $105,232 82
2022 Research $4,521 1
2021 General $74,422 116
2020 General $54,818 58
2019 General $83,310 93
2025 Ownership $1,104 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Amini
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Michael Amini were reported at $272,139. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Michael Amini Orthopaedic Surgery median Middle half National median
2019 $83,310 $644 $140–$2,844 $163
2020 $54,818 $312 $75–$1,860 $114
2021 $74,422 $520 $117–$2,495 $132
2022 $105,232 $598 $128–$2,731 $149
2023 $145,574 $461 $128–$2,264 $160
2024 $230,079 $497 $134–$2,475 $164
2025 $272,139 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $954,988 810 payments
  2. FX Shoulder USA, Inc $3,000 3 payments
  3. restor3d, inc. $2,392 3 payments
  4. Synthes GmbH $1,648 2 payments
  5. Goode Surgical Inc $1,179 2 payments
  6. KCI USA, Inc $850 2 payments
  7. ImpactOrtho, Inc. $360 3 payments
  8. Miach Orthopaedics, Inc. $158 1 payment
  9. Smith+Nephew, Inc. $146 7 payments
  10. Zimmer Biomet Holdings, Inc. $146 2 payments
  11. Other $708 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $745,952 282 payments
  2. Travel and Lodging $131,472 297 payments
  3. Royalty or License $66,127 4 payments
  4. Food and Beverage $17,436 259 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 2 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,500 1 payment
  7. Education $1,088 2 payments
Products named General payments · program years 2019–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $206,432 199 payments
  2. AEQUALIS PERFORM $154,672 66 payments
  3. REUNION Trauma & Extremeties $96,136 89 payments
  4. REUNION Trauma & Extremeties $94,646 47 payments
  5. INSPACE $92,958 80 payments
  6. MAKO $62,920 54 payments
  7. AEQUALIS $57,414 21 payments
  8. ICONIX $54,540 33 payments
  9. AEQUALIS PERFORM REVERSED $48,094 18 payments
  10. TORNIER PERFORM REVERSED GLENOID $42,121 17 payments
  11. Other $335,631 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. FX Shoulder USA, Inc $4,521 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

29

Median for Orthopedic Surgery: 203

Drug cost

$164

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 15 $123
Amoxicillin Generic 14 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$127,490

Of which drugs: $542

Medicare patients

373

Average age 74

Services billed

2,035

222 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Diabetes 29%
Ischemic heart disease 27%
Chronic kidney disease 25%
Depression 23%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 118 693 $532

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

848 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record